Related references
Note: Only part of the references are listed.Dose-Intensive Chemotherapy Including Rituximab in Burkitt's Leukemia or Lymphoma Regardless of Human Immunodeficiency Virus Infection Status Final Results of a Phase 2 Study (Burkimab)
Josep-Maria Ribera et al.
CANCER (2013)
Rituximab in combination with chemotherapy versus chemotherapy alone in HIV-associated non-Hodgkin lymphoma: A pooled analysis of 15 prospective studies
Jorge J. Castillo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Early versus delayed initiation of antiretroviral therapy for Indian HIV-Infected individuals with tuberculosis on antituberculosis treatment
Sanjeev Sinha et al.
BMC INFECTIOUS DISEASES (2012)
Safety and activity of a new intensive short-term chemoimmunotherapy in HIV-positive patients with Burkitt lymphoma
Andres J. M. Ferreri et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Good outcome of AIDS-related Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) with abbreviated cycles of EPOCH-rituximab
K Dunleavy et al.
Infectious Agents and Cancer (2012)
Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma
Joseph A. Sparano et al.
BLOOD (2010)
The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma
Kieron Dunleavy et al.
BLOOD (2010)
Early versus Delayed Fixed Dose Combination Abacavir/Lamivudine/Zidovudine in Patients with HIV and Tuberculosis in Tanzania
Humphrey J. Shao et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2009)
Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study
Julia Bohlius et al.
ANTIVIRAL THERAPY (2009)
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
David Moher et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Incidence of types of cancer among HIV-Infected persons compared with the general population in the United States, 1992-2003
Pragna Patel et al.
ANNALS OF INTERNAL MEDICINE (2008)
Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma:: results of a phase II trial
Josep-Maria Ribera et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma - Comparison of results in human immunodeficiency virus-infected and noninfected patients
Albert Oriol et al.
CANCER (2008)
Management of AIDS-related lymphoma
Alexandra M. Levine
CURRENT OPINION IN ONCOLOGY (2008)
Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia:: a prospective study
Lionel Galicier et al.
BLOOD (2007)
Modern management of non-Hodgkin lymphoma in HIV-infected patients
Nicolas Mounier et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
HIV-associated lymphoma: the evidence for treating aggressively but with caution
Joseph A. Sparano
CURRENT OPINION IN ONCOLOGY (2007)
Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma
Francois Boue et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy
Nicolas Mounier et al.
BLOOD (2006)
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma:: a randomised controlled trial by the MabThera International Trial (MInT) Group
Michael Pfreundschuh et al.
LANCET ONCOLOGY (2006)
Acquired immunodeficiency syndrome-related lymphoma - Simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival - Results of the German Multicenter trial
R Weiss et al.
CANCER (2006)
Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010
LD Kaplan et al.
BLOOD (2005)
A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy
M Bower et al.
ANNALS OF INTERNAL MEDICINE (2005)
Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV associated non-Hodgkin's lymphoma: An eastern cooperative oncology group trial (E1494)
JA Sparano et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology
RF Little et al.
BLOOD (2003)
Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy
WH Wilson et al.
BLOOD (2002)
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
B Coiffier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
HIV-associated non-Hodgkin lymphoma - Incidence, presentation, and prognosis
RF Little et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Intensive chemotherapy (LNHIV-91 regimen) and G-CSF for HIV associated non-Hodgkin's lymphoma
E Oksenhendler et al.
LEUKEMIA & LYMPHOMA (2000)
Share Paper
